Audit: QRS - L-Threonine for Health & Longevity

Audit conducted on 10/09/2026 06:20 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	87
Failed	0
N/A	6
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All QRS content traces to the ER: protocol cells to Therapeutic Protocol, benefit/risk items to the ER tier headings, monitoring rows to the ER biomarker table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious ER phrasing carried over: “Not published” for half-life, “no trial has measured either” in the qualitative assessment.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening detected; the seven avoid-list populations are carried at ER severity.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and Key Interactions both drawn from the ER Key Interactions & Contraindications section; no modifying factor is recategorised.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, study names, NCT identifiers, expert names or brands appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, deflationary register (“called too small to matter”, “rest on animals”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven while remaining accessible; tiers and targets give the reader actionable structure.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence and thresholds; no prescriptive instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No advisory verbs; the fixed footer disclaimer is the only clinical-referral language.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Why-column entries are declarative (“Confirms”, “Detects”, “Separates”); nothing recommends or advises.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address anywhere in the body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language throughout; technical terms appear only where the ER qualifier is load-bearing (eGFR threshold, Child-Pugh Class C).
2.8	Information is presented in a concise and very compact manner	🟢	Every field is condensed to heading or single-clause form.
2.9	It DOES NOT address the reader directly	🟢	Verified: no “you”/”your” tokens in the rendered text.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Tiered benefits/risks, biomarker targets and a dosing ceiling address a proactive, risk-aware reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Presents a titration schedule, a monitoring panel and lab cadence without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes willingness to run baseline labs and a time-limited trial.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states plainly that adequate-protein eaters already exceed the requirement, which is the audience-relevant signal.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Slower aging” is used descriptively; the term “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route of administration is given as “Oral L-threonine”; no colloquial substitutes (“pill”, “shot”, “by mouth”) occur.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and table column headers are byte-identical to [qrs_template].
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables present; marker_#* expands to marker_1..9 and qualitative_item# to 1..4, as the template intends.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against [qrs_template] shows the style block, header block and footer block are byte-identical; only checklist-addressed spans differ.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped into the QRS is empty; Benefits Medium and Risks High carry explanatory ER prose and are handled under 12.5/13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	ER bold labels reused verbatim: “Standard neurological protocol”, “Nutritional repletion protocol”, “Single versus split dosing”, “Half-life”, “Muscle tone and ease of movement”, “Digestive tolerance”, “Energy and exercise recovery”, “Sleep quality”.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No invented labels; time_2_label “Repletion of a dietary shortfall” is lifted verbatim from ER Practical Considerations.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No 🟩/🟥/🟨 or any other emoji in the file; the ER’s “⚠️ Conflicted” marker was correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Each section is condensed to the minimum form the completeness items (8.2, 9.2, 12.x, 13.x, 14.2, 15.2) permit — headings only, no elaborations, no citations; nothing is carried at ER length.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment opens on line 2, immediately after <!doctype html>, before any other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13, inside the comment.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no body element repeats it.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:03" is quoted, which YAML requires because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: l_threonine_2026-0910-0445_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0910-0610, in YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number only; no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: l_threonine_2026-0910-0445_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified: no stray whitespace or unnecessary quoting on any key.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &)	🟢	<title>L-Threonine for Health &amp; Longevity - Quick Reference Sheet</title>; the ampersand is entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &)	🟢	header_topic = “L-Threonine for Health & Longevity”, matching the ER canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	09/10/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0910-0610.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block is byte-identical to the template; no badge, AKA line, version stamp or variant marker was added.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion to the decision-relevant bottom line: requirement already met by ordinary protein intake, one small controlled effect, animal-only for the rest.
7.2	[at_a_glance] is no longer than 60 words	🟢	60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct ER Conclusion passage (lines 455, 457, 461).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms or specialist classifications; “involuntary muscle tightness after nerve damage” replaces “spasticity in upper motor neuron disorders”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, relative risks or statistical results.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from the ER “Populations who should avoid L-Threonine:” list inside Key Interactions & Contraindications.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-list populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is a discrete <li></li> inside the [stop_items] span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER trailing clause after the em-dash was stripped (e.g. “— absolute contraindication; threonine is one of the four restricted precursor amino acids”).
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Qualifiers preserved and trimmed: “stage 4 or 5 (eGFR below 30 mL/min/1.73 m²)”, “(Child-Pugh Class C)”, “Active flare”, “under 18”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation inside parentheses in this list; the items are already plain comma-separated.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, which is correct — the ER names seven populations that should avoid the intervention.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items come from the ER Key Interactions & Contraindications sub-lists (prescription, over-the-counter, supplement, other intervention).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eleven ER interaction bullets present; none duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is a discrete <li></li> inside the [caution_items] span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution —”, “Monitor —” and “Additive and supportive —” clause and its mechanistic rationale was stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drug lists preserved: “(baclofen, tizanidine, dantrolene)”, “(metformin, proton pump inhibitors such as omeprazole, nitrous oxide)”, “(magnesium glycinate, high-dose glycine, valerian, cannabidiol)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation inside parentheses in this list.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, which is correct — the ER names eleven interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action cells derive from the ER Therapeutic Protocol section (lines 337, 339, 347).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two named dosing schedules and the single-versus-split decision are the three actionable aspects; the remaining ER bullets are attributional or population-modifiers.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section supplies at least three distinct actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action fields carry substantive ER-derived content; no placeholder remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Covers the two time-to-effect aspects the ER states (tone change at two weeks; plasma repletion within days) plus the ER Half-life bullet.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High benefit (spasticity, 2 weeks) → Low benefit (repletion, within days) → pharmacokinetic half-life.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct aspects for this row.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields carry substantive ER-derived content.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the row is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Tiers map one-to-one onto the ER Expected Benefits High / Medium / Low / Speculative headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four benefit spans present and correctly named.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the ER sub-headings only; no magnitudes, trial descriptions or mechanisms carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives; the six speculative headings are joined as a plain semicolon list.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_medium carries style="display: none", matching the ER statement that no benefit reaches Medium.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Tiers map one-to-one onto the ER Potential Risks & Side Effects headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four risk spans present and correctly named.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the ER sub-headings only; the NOAEL figure, odds ratio and confidence interval are all left behind.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high carries style="display: none", matching the ER statement that no risk reaches High.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All nine rows derive from the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers are listed with their optimal functional ranges verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated with the ER cadence: baseline, enzymes at 8 weeks / 6 months / annually, amino acids and MMA at 6 months and annually.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All four items come from the “Qualitative markers tracked alongside the labs” list in the ER Monitoring Protocol & Defining Success section.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All four ER qualitative markers are present with their bold labels verbatim.

Issues 10/09/2026 06:20

Pass rate 100.00%. No issues found.

Issues 10/09/2026 06:17

1. 1.3 — Hedge dropped from lede: at_a_glance (line 434) reads “anyone eating adequate protein already takes in several times the amount needed”; the ER Conclusion says “Almost anyone”, so the QRS states as universal what the ER states as near-universal.
2. 1.1 / 4.2 / 4.3 — Time-to-effect cell 3 unsupported and relabelled: time_3_label “Plasma pool expansion” with time_3_value “4 weeks” (lines 525–528) invents a label for the ER’s “Half-life:” bullet and presents the trial’s four-week measurement point as a time-to-effect interval, which the ER does not state.

Fixes 10/09/2026 06:17

1. 1.3 — Hedge restored in lede: at_a_glance changed from “anyone eating adequate protein” to “almost anyone eating adequate protein”, matching the ER Conclusion; the summary remains within the 60-word limit.
2. 1.1 / 4.2 / 4.3 — Time-to-effect cell 3 realigned to the ER: time_3_label changed from the invented “Plasma pool expansion” to the ER’s bold label “Half-life”, time_3_value from the unsupported “4 weeks” to “Not published”, and the sub rewritten to lead with “No elimination half-life has been published”.